Jia Jie Biomedical Co Ltd (4109) - Total Assets
Based on the latest financial reports, Jia Jie Biomedical Co Ltd (4109) holds total assets worth NT$1.92 Billion TWD (≈ $60.57 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jia Jie Biomedical Co Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Jia Jie Biomedical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Jia Jie Biomedical Co Ltd market capitalisation for the company's overall valuation and market capitalisation.
Jia Jie Biomedical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Jia Jie Biomedical Co Ltd's total assets of NT$1.92 Billion consist of 30.4% current assets and 69.6% non-current assets. Review debt load of Jia Jie Biomedical Co Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 15.7% |
| Accounts Receivable | NT$44.99 Million | 2.4% |
| Inventory | NT$27.68 Million | 1.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Jia Jie Biomedical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Jia Jie Biomedical Co Ltd share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jia Jie Biomedical Co Ltd's current assets represent 30.4% of total assets in 2025, an increase from 27.9% in 2015.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2025, up from 12.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 2.4% of total assets.
Jia Jie Biomedical Co Ltd Competitors by Total Assets
Key competitors of Jia Jie Biomedical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Grupo Bimbo S.A.B. de C.V
MX:BIMBOA
|
Mexico | MX$414.57 Billion |
|
Britannia Industries Limited
NSE:BRITANNIA
|
India | Rs97.32 Billion |
|
Tingyi (Cayman Islands) Holding Corp
F:TYG
|
Germany | €54.94 Billion |
|
Saputo Inc
TO:SAP
|
Canada | CA$13.61 Billion |
|
ORKLA ADR/1 NK 625
F:OKL0
|
Germany | €88.70 Billion |
|
Guangdong Haid Group Co Ltd
SHE:002311
|
China | CN¥55.29 Billion |
|
Qianhe Condiment&Food Co Ltd
SHG:603027
|
China | CN¥4.46 Billion |
|
Aryzta AG
SW:ARYN
|
Switzerland | CHF1.89 Billion |
Jia Jie Biomedical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.08 | 3.67 | 5.87 |
| Quick Ratio | 3.85 | 3.56 | 5.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$450.32 Million | NT$522.53 Million | NT$298.84 Million |
Jia Jie Biomedical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jia Jie Biomedical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.80 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 27.4% |
| Total Assets | NT$1.89 Billion |
| Market Capitalization | $41.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jia Jie Biomedical Co Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jia Jie Biomedical Co Ltd's assets grew by 27.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jia Jie Biomedical Co Ltd (2015–2025)
The table below shows the annual total assets of Jia Jie Biomedical Co Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.89 Billion ≈ $59.51 Million |
+27.43% |
| 2024-12-31 | NT$1.48 Billion ≈ $46.70 Million |
+4.91% |
| 2023-12-31 | NT$1.41 Billion ≈ $44.51 Million |
+40.73% |
| 2022-12-31 | NT$1.00 Billion ≈ $31.63 Million |
-1.71% |
| 2021-12-31 | NT$1.02 Billion ≈ $32.18 Million |
+3.23% |
| 2020-12-31 | NT$989.41 Million ≈ $31.17 Million |
+15.61% |
| 2019-12-31 | NT$855.81 Million ≈ $26.96 Million |
-23.49% |
| 2018-12-31 | NT$1.12 Billion ≈ $35.24 Million |
-15.33% |
| 2017-12-31 | NT$1.32 Billion ≈ $41.62 Million |
-19.80% |
| 2016-12-31 | NT$1.65 Billion ≈ $51.90 Million |
+4.33% |
| 2015-12-31 | NT$1.58 Billion ≈ $49.75 Million |
-- |
About Jia Jie Biomedical Co Ltd
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jel… Read more